申请人:Nilsson Magnus
公开号:US20090023748A1
公开(公告)日:2009-01-22
Compounds of the formula II:
wherein
R
2
is the side chain of leucine, isoleucine, cyclohexylglycine, O-methyl threonine, 4-fluoroleucine or 3-methoxyvaline;
R
3
is H, methyl or F;
Rq is trifluoromethyl and Rq′ is H or Rq and Rq′ define keto;
Q is a p-(C
1
-C
6
alkylsulphonyl)phenyl- or an optionally substituted 4-(C
1
-C
6
alkyl)piperazin-1-yl-thiazol-4-yl- moiety have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.
公式II的化合物:
其中,
R2是亮氨酸、异亮氨酸、环己基甘氨酸、O-甲基苏氨酸、4-氟亮氨酸或3-甲氧基缬氨酸的侧链;
R3是H、甲基或F;
Rq是三氟甲基,Rq′是H或Rq,且Rq和Rq′定义酮基;
Q是p-(C1-C6烷基磺酰)苯基或可选取代的4-(C1-C6烷基)哌嗪-1-基噻唑-4-基基团。
这些化合物在治疗因过度表达或激活K型蛋白酶引起的疾病方面具有应用价值,例如骨质疏松症、骨关节炎、类风湿性关节炎或骨转移等。